| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/17425255.2016.1162785 |
| P698 | PubMed publication ID | 26950189 |
| P50 | author | Richard M. Anthony | Q56191657 |
| Jan-Willem C Alffenaar | Q88470065 | ||
| Dick van Soolingen | Q47087451 | ||
| P2093 | author name string | Bob Wilffert | |
| Mathieu S Bolhuis | |||
| Marlanka A Zuur | |||
| Wiel de Lange | |||
| Tridia van der Laan | |||
| Alice den Hertog | |||
| P2860 | cites work | Transformative tools for tackling tuberculosis | Q26784084 |
| Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis | Q28289915 | ||
| Pharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosis | Q28542435 | ||
| The human immune response to tuberculosis and its treatment: a view from the blood | Q28544750 | ||
| Cytokine Kinetics in the First Week of Tuberculosis Therapy as a Tool to Confirm a Clinical Diagnosis and Guide Therapy | Q28545824 | ||
| High Prevalence of inhA Promoter Mutations among Patients with Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa | Q28547703 | ||
| Effect of standard tuberculosis treatment on plasma cytokine levels in patients with active pulmonary tuberculosis | Q28729980 | ||
| Rapid molecular detection of tuberculosis and rifampin resistance | Q29617127 | ||
| Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014 | Q30300207 | ||
| A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis | Q33383681 | ||
| Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis | Q33387661 | ||
| Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples | Q33547441 | ||
| Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. | Q33827163 | ||
| Simple rapid near-patient diagnostics for tuberculosis remain elusive--is a "treat-to-test" strategy more realistic? | Q34071357 | ||
| Re-evaluation of the critical concentration for ethambutol antimicrobial sensitivity testing on the MGIT 960. | Q34259008 | ||
| Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis | Q34285599 | ||
| IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection | Q34395156 | ||
| In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB | Q34591451 | ||
| Quantification of rifapentine, a potent antituberculosis drug, from dried blood spot samples using liquid chromatographic-tandem mass spectrometric analysis | Q34596844 | ||
| Early specific host response associated with starting effective tuberculosis treatment in an infection controlled placebo controlled mouse study | Q34612744 | ||
| Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis | Q34933405 | ||
| Therapeutic drug monitoring in the treatment of tuberculosis | Q34967044 | ||
| IP-10 measured by Dry Plasma Spots as biomarker for therapy responses in Mycobacterium Tuberculosis infection | Q35188912 | ||
| Clinical evaluation of tuberculosis viability microscopy for assessing treatment response | Q35207458 | ||
| Molecular bacterial load assay, a culture-free biomarker for rapid and accurate quantification of sputum Mycobacterium tuberculosis bacillary load during treatment | Q35530606 | ||
| Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability | Q35532853 | ||
| Diagnostic Performance of the New Version (v2.0) of GenoType MTBDRsl Assay for Detection of Resistance to Fluoroquinolones and Second-Line Injectable Drugs: a Multicenter Study | Q35693044 | ||
| Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis. | Q35746184 | ||
| Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis | Q35859862 | ||
| Dynamics of interferon-gamma release assay and cytokine profiles in blood and respiratory tract specimens from mice with tuberculosis and the effect of therapy | Q35942336 | ||
| Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens | Q35947438 | ||
| Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study | Q36084640 | ||
| Predicting differential rifamycin resistance in clinical Mycobacterium tuberculosis isolates by specific rpoB mutations. | Q36169719 | ||
| Biomarkers for Tuberculosis Based on Secreted, Species-Specific, Bacterial Small Molecules | Q36250234 | ||
| Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis | Q36364155 | ||
| Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy | Q36379388 | ||
| The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. | Q36599937 | ||
| Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana | Q37145913 | ||
| Serum drug concentrations predictive of pulmonary tuberculosis outcomes | Q37213037 | ||
| Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens | Q37214096 | ||
| Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs | Q37274688 | ||
| Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. | Q37410535 | ||
| Gamma interferon release assays for detection of Mycobacterium tuberculosis infection | Q37544916 | ||
| Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 2: second line drugs | Q37810481 | ||
| Dried blood spots, pharmacokinetic studies and better medicines for children. | Q37859735 | ||
| The ins and outs of Mycobacterium tuberculosis drug susceptibility testing | Q37883484 | ||
| Dried blood spots: a new tool for tuberculosis treatment optimization | Q37915554 | ||
| Rapid diagnosis of pyrazinamide-resistant multidrug-resistant tuberculosis using a molecular-based diagnostic algorithm. | Q51081950 | ||
| Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity. | Q51168151 | ||
| Extension of the intensive phase reduces relapse but not failure in a regimen with rifampicin throughout. | Q51362998 | ||
| Molecular drug susceptibility testing in the Netherlands: performance of the MTBDRplus and MTBDRsl assays. | Q51624034 | ||
| Differential cytokine secretion and early treatment response in patients with pulmonary tuberculosis. | Q51838282 | ||
| Determination of moxifloxacin in dried blood spots using LC-MS/MS and the impact of the hematocrit and blood volume. | Q53082804 | ||
| Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. | Q53123391 | ||
| A Step toward an Optimized Rifampin Dose Completed. | Q53791744 | ||
| Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study. | Q53833121 | ||
| Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC-MS/MS. | Q54290346 | ||
| Early tuberculosis treatment monitoring by Xpert(R) MTB/RIF. | Q54312164 | ||
| Acquired Drug Resistance: We Can Do More Than We Think! | Q58033436 | ||
| Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics | Q58879828 | ||
| Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. | Q38164652 | ||
| The early bactericidal activity of antituberculosis drugs | Q38176039 | ||
| Therapeutic drug monitoring in the treatment of tuberculosis: an update | Q38213320 | ||
| Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples. | Q38369608 | ||
| Evaluation of the Genotype® MTBDRplus assay as a tool for drug resistance surveys. | Q38422698 | ||
| Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia | Q38502298 | ||
| Clinical value of whole-genome sequencing of Mycobacterium tuberculosis | Q38567338 | ||
| Multi-center evaluation of a user-friendly lateral flow assay to determine IP-10 and CCL4 levels in blood of TB and non-TB cases in Africa | Q38858066 | ||
| Limited sampling strategies to predict the area under the concentration-time curve for rifampicin | Q39200873 | ||
| Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis | Q39410604 | ||
| Bedaquiline susceptibility testing of Mycobacterium tuberculosis in an automated liquid culture system | Q39529865 | ||
| Disputed rpoB mutations can frequently cause important rifampicin resistance among new tuberculosis patients | Q39549690 | ||
| New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability | Q39895097 | ||
| Highly successful treatment outcome of multidrug-resistant tuberculosis in the Netherlands, 2000-2009. | Q41346846 | ||
| Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance | Q41876123 | ||
| Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis | Q41968982 | ||
| Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations | Q42062555 | ||
| Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study. | Q42201109 | ||
| Development and validation of a new UPLC-PDA method to quantify linezolid in plasma and in dried plasma spots. | Q42249983 | ||
| Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST. | Q42430318 | ||
| Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement | Q42715629 | ||
| Wild-type MIC distributions must be considered to set clinically meaningful susceptibility testing breakpoints for all bacterial pathogens, including Mycobacterium tuberculosis | Q42881940 | ||
| Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients | Q42978707 | ||
| Method for simultaneous analysis of nine second-line anti-tuberculosis drugs using UPLC-MS/MS. | Q43745618 | ||
| Efficacy of IP-10 as a biomarker for monitoring tuberculosis treatment | Q43879619 | ||
| Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis | Q44849406 | ||
| Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience | Q45339042 | ||
| Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin | Q45346443 | ||
| Therapeutic drug monitoring in the treatment of tuberculosis: a retrospective analysis | Q46272585 | ||
| Can inhA mutation predict ethionamide resistance? | Q46280514 | ||
| Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients | Q46573371 | ||
| Simultaneous staining of sputum smears for acid-fast and lipid-containing Myobacterium tuberculosis can enhance the clinical evaluation of antituberculosis treatments | Q46747793 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International | Q24082749 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | tuberculosis | Q12204 |
| P304 | page(s) | 509-521 | |
| P577 | publication date | 2016-03-07 | |
| P1433 | published in | Expert Opinion on Drug Metabolism & Toxicology | Q5421205 |
| P1476 | title | Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis | |
| P478 | volume | 12 |
| Q45072459 | A Systematic Review Of Salivary Versus Blood Concentrations Of Anti-Tuberculosis Drugs And Their Potential For Salivary Therapeutic Drug Monitoring |
| Q58578267 | A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs |
| Q50068179 | Bedaquiline resistance: Its emergence, mechanism and prevention |
| Q42285243 | Discovery and Validation of a Six-Marker Serum Protein Signature for the Diagnosis of Active Pulmonary Tuberculosis |
| Q91726570 | Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis |
| Q39026859 | How do we measure adherence to anti-tuberculosis treatment? |
| Q50134142 | In vitro drug susceptibility of Mycobacterium tuberculosis for amikacin, kanamycin and capreomycin |
| Q30275673 | Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers |
| Q90212817 | Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients |
| Q93171585 | Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with Tuberculosis |
| Q52684511 | Plasma Levels of Rifampin Correlate with the Tuberculosis Drug Activity Assay. |
| Q57024955 | Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study |
| Q58100705 | Population pharmacokinetic model and limited sampling strategies for personalized dosing of levofloxacin in tuberculosis patients |
| Q45237067 | Reply to Alffenaar et al. |
| Q45046059 | Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians. |
| Q42281128 | Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes. |
Search more.